Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim to provide manufacturing services for MorphoSys

Boehringer Ingelheim to provide manufacturing services for MorphoSys

17th March 2011

Boehringer Ingelheim is to provide contract manufacturing services to support new drug development initiatives conducted by MorphoSys.

A new biopharmaceutical manufacturing agreement has been signed that will see Boehringer Ingelheim assist with process development and clinical material production for MorphoSys' MOR208 programme.

This project concerns a monoclonal anti-CD19 antibody that is currently in phase I testing against chronic lymphocytic leukaemia, with the new arrangement having been agreed at an early stage to increase the programme's value.

Dr Marlies Sproll, chief scientific officer of MorphoSys, stated that this supply deal will help to prevent any potential bottlenecks in clinical trial supplies.

Simon Sturge, corporate senior vice-president of the biopharmaceuticals division at Boehringer Ingelheim, added: "The combination of MorphoSys' successful track record in the discovery and clinical development of antibody-based therapeutics and our proven competence in technical development and manufacturing will be an optimal fit."

Last month, Boehringer Ingelheim signed an agreement with Pfenex that will allow the company and its contract manufacturing clients to utilise Pfenex's expression platform technology in drug production.ADNFCR-8000103-ID-800466060-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.